Phase II study to evaluate safety and efficacy of investigative medication in adults with generalized MG
A clinical-stage biopharmaceutical company developing treatments for autoimmune diseases brought in Raremark to boost recruitment to a Phase II study of an experimental drug for generalized myasthenia gravis (MG); a super-hot area for clinical research experiencing high competition for eligible patients.By reaching out to Raremark’s online community of MG patients, which is the largest in the world in this condition, we were able to boost enrollment by 25% within 90 days - saving the sponsors at least three months off their recruitment timeline.
Download the Xperiome case study Phase II study to evaluate safety and efficacy of investigative medication in adults with generalized MG.
Sign up for updates
If you’d like to receive Xperiome updates directly in your inbox, just click ‘Sign up’ and fill in your details.